Muhammad Huzaifa Khattak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Huzaifa Khattak has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Bilal Wazir Khan
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
8 shared publications - Aleena Amir Malik
Department of Medicine, United Medical and Dental College, Karachi, Pakistan
4 shared publications - Muhammad Maaz Amjad
Khyber Medical College, Peshawar, Pakistan
4 shared publications - Tayyaba Ikram Qazi
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
4 shared publications Humaira Bibi
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
3 shared publications- Muhammad Yahya
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
3 shared publications
Latest Publications
- 22 September 2026
- Published by Springer Nature in International Journal of Obesity
- p. 1-13
Influence of Lactobacillus plantarum on anthropometric and inflammatory parameters in obesity: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Background The global obesity epidemic, rooted in chronic inflammation and metabolic dysfunction, necessitates novel interventions; however, evidence regarding the efficacy of Lactobacillus plantarum remains inconsistent. Objective To evaluate the impact of L. plantarum on obesity-related outcomes in adults via a systematic review and meta-analysis of RCTs. Methods Following PRISMA guidelines and registered in PROSPERO (CRD420251102722), we systematically searched PubMed, Cochrane Library, and Google Scholar through May 2025. Eighteen RCTs (1310 participants) involving non-diabetic adults with BMI ≥ 25 kg/m² were included. Primary outcomes were body weight and BMI; secondary outcomes included lipid profile, glycemic indices, inflammatory biomarkers, liver enzymes, and body composition. ROB 2.0 and GRADE were used to assess bias and evidence certainty. Results L. plantarum supplementation significantly reduced body weight (MD = −1.23 kg; 95% CI: −1.97 to −0.49; p = 0.001; I² = 49%) and BMI (MD = −0.28; 95% CI: −0.54 to −0.02; p = 0.03; I² = 77%). Subgroup analysis suggested these reductions were more pronounced with multi-strain formulations than single-strain L. plantarum; however, tests for subgroup interaction were non-significant, indicating insufficient evidence to confirm a true difference in effect by formulation type. Improvements were also noted in waist circumference (MD = −1.36 cm; p = 0.003) and liver enzymes. High-certainty evidence supported body weight reduction; moderate-certainty evidence supported reductions in BMI, waist circumference, fat mass, and liver enzymes; low-certainty evidence was found for lipid, glycemic, and inflammatory outcomes. Conclusions L. plantarum, particularly in multi-strain formulations, may provide modest yet clinically meaningful benefits in obesity management. Standardized, long-term trials are warranted. Registry and registry number for systematic reviews or meta-analyses The systematic review and meta-analysis were registered on PROSPERO under the ID: CRD420251102722.
- 22 September 2026
- Published by Springer Nature in International Journal of Obesity
- p. 1-13
Influence of Lactobacillus plantarum on anthropometric and inflammatory parameters in obesity: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Background The global obesity epidemic, rooted in chronic inflammation and metabolic dysfunction, necessitates novel interventions; however, evidence regarding the efficacy of Lactobacillus plantarum remains inconsistent. Objective To evaluate the impact of L. plantarum on obesity-related outcomes in adults via a systematic review and meta-analysis of RCTs. Methods Following PRISMA guidelines and registered in PROSPERO (CRD420251102722), we systematically searched PubMed, Cochrane Library, and Google Scholar through May 2025. Eighteen RCTs (1310 participants) involving non-diabetic adults with BMI ≥ 25 kg/m² were included. Primary outcomes were body weight and BMI; secondary outcomes included lipid profile, glycemic indices, inflammatory biomarkers, liver enzymes, and body composition. ROB 2.0 and GRADE were used to assess bias and evidence certainty. Results L. plantarum supplementation significantly reduced body weight (MD = −1.23 kg; 95% CI: −1.97 to −0.49; p = 0.001; I² = 49%) and BMI (MD = −0.28; 95% CI: −0.54 to −0.02; p = 0.03; I² = 77%). Subgroup analysis suggested these reductions were more pronounced with multi-strain formulations than single-strain L. plantarum; however, tests for subgroup interaction were non-significant, indicating insufficient evidence to confirm a true difference in effect by formulation type. Improvements were also noted in waist circumference (MD = −1.36 cm; p = 0.003) and liver enzymes. High-certainty evidence supported body weight reduction; moderate-certainty evidence supported reductions in BMI, waist circumference, fat mass, and liver enzymes; low-certainty evidence was found for lipid, glycemic, and inflammatory outcomes. Conclusions L. plantarum, particularly in multi-strain formulations, may provide modest yet clinically meaningful benefits in obesity management. Standardized, long-term trials are warranted. Registry and registry number for systematic reviews or meta-analyses The systematic review and meta-analysis were registered on PROSPERO under the ID: CRD420251102722.
- 19 September 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-27
Transradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of 32 studies
1. Diagnostic cerebral angiography is the gold standard for evaluating cerebrovascular pathologies, including intracranial aneurysms, arteriovenous malformations, carotid artery stenosis, and vascu...
- 19 September 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-27
Transradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of 32 studies
1. Diagnostic cerebral angiography is the gold standard for evaluating cerebrovascular pathologies, including intracranial aneurysms, arteriovenous malformations, carotid artery stenosis, and vascu...
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.
- 17 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.
- 17 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.
- 10 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10001-10017
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Purpose: To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials. Methods: This systematic review and meta‐analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420261303350). PubMed, Embase and Scopus were searched from inception to March 2026 for randomised controlled trials comparing oral PCSK9 inhibitors with placebo in adults with hypercholesterolemia. Primary outcomes were changes in low‐density lipoprotein cholesterol (LDL‐C) and triglycerides. Secondary outcomes included other lipid parameters, adverse events and mortality. Random‐effects models were used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Quality of the included studies was assessed using the RoB2 tool and certainty of evidence was assessed using the GRADE approach. Results: Five randomised controlled trials ( n = 4268) were included. Oral PCSK9 inhibitors significantly reduced LDL‐C (MD −49.49 mg/dL; 95% CI −54.81 to −44.18; p < 0.00001) and triglycerides (MD −11.65 mg/dL; 95% CI −15.53 to −7.78; p < 0.00001). Significant reductions were also observed in non‐HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol. Dose‐dependent effects were noted, with greater reductions at higher doses. No significant differences were observed in mortality or overall adverse events. Treatment discontinuation due to adverse events was lower with intervention. Conclusions: Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short‐term safety profile. However, the available evidence is derived primarily from short‐term randomised trials evaluating surrogate lipid outcomes. Larger randomised trials with longer follow‐up and cardiovascular outcome data are needed to better define the long‐term clinical role of oral PCSK9 inhibitors.
- 10 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10001-10017
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Purpose: To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials. Methods: This systematic review and meta‐analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420261303350). PubMed, Embase and Scopus were searched from inception to March 2026 for randomised controlled trials comparing oral PCSK9 inhibitors with placebo in adults with hypercholesterolemia. Primary outcomes were changes in low‐density lipoprotein cholesterol (LDL‐C) and triglycerides. Secondary outcomes included other lipid parameters, adverse events and mortality. Random‐effects models were used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Quality of the included studies was assessed using the RoB2 tool and certainty of evidence was assessed using the GRADE approach. Results: Five randomised controlled trials ( n = 4268) were included. Oral PCSK9 inhibitors significantly reduced LDL‐C (MD −49.49 mg/dL; 95% CI −54.81 to −44.18; p < 0.00001) and triglycerides (MD −11.65 mg/dL; 95% CI −15.53 to −7.78; p < 0.00001). Significant reductions were also observed in non‐HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol. Dose‐dependent effects were noted, with greater reductions at higher doses. No significant differences were observed in mortality or overall adverse events. Treatment discontinuation due to adverse events was lower with intervention. Conclusions: Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short‐term safety profile. However, the available evidence is derived primarily from short‐term randomised trials evaluating surrogate lipid outcomes. Larger randomised trials with longer follow‐up and cardiovascular outcome data are needed to better define the long‐term clinical role of oral PCSK9 inhibitors.
- Open Access
- 21 July 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Endoscopic versus open radial artery harvesting for coronary artery bypass grafting: an updated systematic review, meta-analysis, and GRADE assessment
Endoscopic radial artery harvesting (ERAH) is a minimally invasive alternative to open radial artery harvesting (ORAH) for coronary artery bypass grafting
- 21 July 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessEndoscopic versus open radial artery harvesting for coronary artery bypass grafting: an updated systematic review, meta-analysis, and GRADE assessment
Endoscopic radial artery harvesting (ERAH) is a minimally invasive alternative to open radial artery harvesting (ORAH) for coronary artery bypass grafting
- Open Access
- 5 May 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2648406
Comparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis
Acne vulgaris is a chronic inflammatory disease and is one of the leading causes of dermatological morbidities among young adults. Doxycycline is widely recommended as first-line therapy for moderate to severe acne; however, its use is limited. To systematically compare the efficacy and safety of oral azithromycin pulse therapy versus doxycycline in patients with moderate to severe acne vulgaris. This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive literature search on different databases was performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models based on heterogeneity. A total of 23 comparative studies comprising 2,769 patients were included. Pooled analysis demonstrated a statistically significant improvement in global acne severity favoring azithromycin (GAGS reduction: MD 1.81; 95% CI 1.28-2.34; I2 = 0%). Azithromycin achieved a significantly greater reduction in non-inflammatory lesion counts (MD -7.56; 95% CI -14.33 to -0.79). No significant differences were observed in inflammatory lesion reduction (MD 1.08; 95% CI -0.03 to 2.18). Oral azithromycin pulse therapy appears to have similar efficacy, better tolerability, and fewer side effects as compared to doxycycline.
- 5 May 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2648406
Open AccessComparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis
Acne vulgaris is a chronic inflammatory disease and is one of the leading causes of dermatological morbidities among young adults. Doxycycline is widely recommended as first-line therapy for moderate to severe acne; however, its use is limited. To systematically compare the efficacy and safety of oral azithromycin pulse therapy versus doxycycline in patients with moderate to severe acne vulgaris. This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive literature search on different databases was performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models based on heterogeneity. A total of 23 comparative studies comprising 2,769 patients were included. Pooled analysis demonstrated a statistically significant improvement in global acne severity favoring azithromycin (GAGS reduction: MD 1.81; 95% CI 1.28-2.34; I2 = 0%). Azithromycin achieved a significantly greater reduction in non-inflammatory lesion counts (MD -7.56; 95% CI -14.33 to -0.79). No significant differences were observed in inflammatory lesion reduction (MD 1.08; 95% CI -0.03 to 2.18). Oral azithromycin pulse therapy appears to have similar efficacy, better tolerability, and fewer side effects as compared to doxycycline.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Is Ivermectin Associated With Better Treatment Success and Tolerability Than Topical Permethrin in Scabies Patients? A Systematic Review and Meta‐Analysis
Background: Scabies is an infectious parasitic integumentary pathology affecting both pediatric and adult participants globally, specifically in resource‐limited settings. Topical permethrin is commonly advised as the preferred regimen, whereas oral and topical ivermectin have emerged as alternative regimens. Objective: This study aims to assess the safety and efficacy of oral or topical ivermectin compared to topical permethrin alone for the treatment of scabies in both pediatric and adult patients. Methods: A systematic search of four databases (PubMed, Google Scholar, Scopus, and Embase) was conducted from inception to November 2025. Data were analyzed using a random‐effects model (REML estimator) to calculate risk ratios (RRs) and mean differences. To prevent unit‐of‐analysis errors, overarching estimates utilized deduplicated data. Advanced influence diagnostics (leave‐one‐out sensitivity, Baujat plots, and GOSH plots) were employed to rigorously evaluate data stability and outcome fragility. Results: In this meta‐analysis, 38 studies met the inclusion criteria, encompassing 5604 participants. Permethrin demonstrated a robust and highly significant early clinical cure advantage over ivermectin at Week 1 (RR 1.40; 95% CI 1.22–1.62; p < 0.0001; I 2 = 81.1%). While permethrin maintained a marginal statistical superiority at Week 2 (RR 1.11; 95% CI 1.01–1.22), extensive sensitivity analyses revealed this finding to be highly fragile and dependent on outliers. By Weeks 3, 4, and ≥ 6 , comparative efficacy converged, demonstrating no significant difference between the two treatments (RR 1.02 at ≥ 6 weeks; I 2 = 0%). Continuous meta‐regression indicated no significant temporal shift in comparative efficacy over the last 25 years. Conclusion: Low‐to‐moderate certainty evidence suggests that permethrin exhibits superior acute efficacy and faster initial clearance during the first week of treatment compared to ivermectin. However, long‐term efficacy is equivalent. Ivermectin remains a highly viable and equally effective alternative for the definitive management of scabies, particularly when topical application is infeasible or poorly tolerated.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessIs Ivermectin Associated With Better Treatment Success and Tolerability Than Topical Permethrin in Scabies Patients? A Systematic Review and Meta‐Analysis
Background: Scabies is an infectious parasitic integumentary pathology affecting both pediatric and adult participants globally, specifically in resource‐limited settings. Topical permethrin is commonly advised as the preferred regimen, whereas oral and topical ivermectin have emerged as alternative regimens. Objective: This study aims to assess the safety and efficacy of oral or topical ivermectin compared to topical permethrin alone for the treatment of scabies in both pediatric and adult patients. Methods: A systematic search of four databases (PubMed, Google Scholar, Scopus, and Embase) was conducted from inception to November 2025. Data were analyzed using a random‐effects model (REML estimator) to calculate risk ratios (RRs) and mean differences. To prevent unit‐of‐analysis errors, overarching estimates utilized deduplicated data. Advanced influence diagnostics (leave‐one‐out sensitivity, Baujat plots, and GOSH plots) were employed to rigorously evaluate data stability and outcome fragility. Results: In this meta‐analysis, 38 studies met the inclusion criteria, encompassing 5604 participants. Permethrin demonstrated a robust and highly significant early clinical cure advantage over ivermectin at Week 1 (RR 1.40; 95% CI 1.22–1.62; p < 0.0001; I 2 = 81.1%). While permethrin maintained a marginal statistical superiority at Week 2 (RR 1.11; 95% CI 1.01–1.22), extensive sensitivity analyses revealed this finding to be highly fragile and dependent on outliers. By Weeks 3, 4, and ≥ 6 , comparative efficacy converged, demonstrating no significant difference between the two treatments (RR 1.02 at ≥ 6 weeks; I 2 = 0%). Continuous meta‐regression indicated no significant temporal shift in comparative efficacy over the last 25 years. Conclusion: Low‐to‐moderate certainty evidence suggests that permethrin exhibits superior acute efficacy and faster initial clearance during the first week of treatment compared to ivermectin. However, long‐term efficacy is equivalent. Ivermectin remains a highly viable and equally effective alternative for the definitive management of scabies, particularly when topical application is infeasible or poorly tolerated.